Alnylam Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of Marketing Authorization Application
January 26, 2018 at 02:30 am IST
Alnylam Pharmaceuticals, Inc. announced that the European Medicines Agency has accepted the Marketing Authorization Application (MAA) and initiated its review for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis. The filing of the MAA was previously announced on December 18, 2017, and patisiran was previously granted accelerated assessment by the EMA, potentially reducing the Agency’s evaluation time from 210 to 150 days.